In a recent news piece, Massachusetts General Hospital (MGH) chose to highlight Cure Alzheimer's Fund's support of research through the lab of Dr. Rudy Tanzi.
MGH praises the venture capital approach taken by CAF co-founders Jeff and Jacqui Morby, enabling researchers like Tanzi to take risks and pursue "paradigm changing" studies. And the risks have paid off: According to MGH, the scientific results brought about by CAF-funded research are "nothing short of game changing, as Mass General researchers resolve some long-unanswered questions about how Alzheimer’s disease develops."
Released today, the President's Fiscal Year 2016 Budget includes several important increases for medical research. The National Institutes of Health (NIH) will receive an additional $1 billion, incuding $68 million for the National Institute on Aging. These represent roughly a 1.1% and a 3.3% increase in NIH and NIA's respective budgets.
Building on its enormously successful “Whole Genome Sequencing” Project, which identified nearly 1,000 new genetic mutations in more than 50 different genes, Cure Alzheimer's Fund has announced a new, even more ambitious multiyear, $50 million plus program titled “Genes to Therapies” (G2T). Simply put, the new project’s goal is to use the most promising recent genetic discoveries to develop drugs that would stop the disease at three separate stages:
Cure Alzheimer's Fund Chairman and Co-Founder Jeff Morby and Co-Founder Jacqui Morby were featured for their support of Alzheimer's research in Sunday's Pittsburgh Post-Gazette. The article highlights Cure Alzheimer's Fund's success and the commitment of its founders and board to cover all operating costs. The Post-Gazette also describes the origins of the fund, which started off under the Pittsburgh Foundation until the Morbys garnered enough support to launch a public charity.
New research by David Holtzman, M.D. at the Washington University School of Medicine points to a sleep regulation protein in the brain as a possible target for Alzheimer's disease treatment or prevention. The protein, called orexin, plays a role in rousing the brain from sleep.
Matthew Szulik, 58, of Boston has always put his family first. Despite building a reputation as one of the most innovative and creative technology entrepreneurs in the world, New Bedford, Massachusetts, native Szulik left his job to care for a family member with Alzheimer’s.
Sherry Sharp, wife of CarMax founder Richard L. Sharp, today announced that she has agreed to serve on Cure Alzheimer’s Fund’s Board of Directors. In her husband’s honor, she is going to do everything she can to further our mission to fund research with the highest probability of preventing, slowing, or reversing Alzheimer’s disease through venture-based philanthropy.
Recent months have witnessed three remarkable developments in projects supported by Cure Alzheimer’s Fund.
From the age of 2, when he disassembled his brother’s mechanical duck and his father praised him for his curiosity, Charlie Glabe was always interested in the way things work. Today, Charlie is a highly respected neuroscientist and a member of the Cure Alzheimer’s Fund Research Consortium.
“For the first time, and to the astonishment of many of their colleagues, researchers created what they call Alzheimer’s in a Dish — a petri dish with human brain cells that develop the telltale structures of Alzheimer’s disease.”
© 2005-2015 Cure Alzheimer's Fund. All rights reserved.